GlassScriptPhysician profile
Abraham Samra
NPI 1740724376
$2,216.51
in general payments reported to CMS, 2019-2025
18 companies · $465 in 2025
The $465 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $744 · 2023: $640 · 2024: $367 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,354 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,354.30 |
| Education | $118.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $485.17 | 2022-2023 | Lokelma, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $425.83 | 2023-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $193.28 | 2022-2023 | Jynarque |
| Otsuka America Pharmaceutical, INC. | $152.98 | 2023-2025 | Jynarque |
| Vifor Pharma, INC. | $140.42 | 2022-2023 | Veltassa, Korsuva |
| Amgen INC. | $126.36 | 2025 | Tavneos |
| Aurinia Pharma U.S., INC. | $125.77 | 2024 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $125.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $115.91 | 2024-2025 | |
| Horizon Therapeutics Plc | $114.92 | 2022 | |
| Smith+Nephew, INC. | $40.14 | 2023 | Grafix Pl |
| Fresenius USA Marketing, INC. | $35.59 | 2024 | Velphoro |
| Abbvie INC. | $26.92 | 2023 | Vraylar |
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
| Lilly USA, LLC | $23.99 | 2024 | Jardiance |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recor Medical INC | $23.04 | 2025 | Paradise Ultrasound Renal Denervation System |
| Medtronic, INC. | $21.11 | 2025 | Symplicity G3 |
| Glaxosmithkline, LLC. | $15.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abraham Samra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.